Why are Indian pharma firms cutting back on R&D?

I gather that Indian pharma companies budgets for R&D have never been particularly generous.

However, I gather that they are being cut even further. Many whole projects have been slashed in at least one of India's top pharma companies, and foreign visits are no longer
allowed at all.

In other companies, R&D has been separated like a pariah into a spin-off.

Insiders tel me that even more changes may come soon - and they may not be positive ones.

It would be useful to understand the reasoning behind this downgrading of R&D.

Do our firms really want to be involved only in generics and never become pioneers and brand-builders? Sphere: Related Content